Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Jean-Paul Clozel"'
Autor:
Jean-Paul Clozel, Marc de Gasparo, Patrick Hess, Patrick Bruneval, Barbara Nuesslein-Hildesheim
Publikováno v:
Journal of the Renin-Angiotensin-Aldosterone System, Vol 1 (2000)
There is increasing evidence to suggest endothelial dysfunction as a critical factor in vascular diseases. Genetically predisposed spontaneously hypertensive rats (SHR) treated with inhibitors of nitric oxide (NO) synthase, develop a severe hypertens
Autor:
Jean-Paul Clozel, Horst A. Welker, Patrick du Souich, Marc Lefebvre, G Caillé, Jean‐Guy Besner
Publikováno v:
Clinical Pharmacology & Therapeutics. 67:249-257
Background Increasing oral doses of mibefradil (10 to 320 mg) decrease its apparent oral clearance; however, intravenous doses up to 80 mg do not reduce its systemic clearance. This study aimed to understand the mechanisms underlying the zero-order k
Autor:
Murielle M. Véniant, Robert Wolfgang, Jean-Paul Clozel, Changbin Qiu, Walter Fischli, Urs Sprecher
Publikováno v:
Journal of Cardiovascular Pharmacology. 34:674-682
Renin is produced by the kidney and secreted into the systemic circulation. However, its biochemical and physiological role of regulating renal blood flow with changing renal perfusion pressure (RPP) is not fully understood. In this study, the functi
Publikováno v:
Journal of Cardiovascular Pharmacology. 34:199-205
Endothelin (ET) may play an important role in the pathogenesis of vasoconstriction and acute renal failure after aortic cross-clamping (ACC). However, the relative contribution of the ET(A) and ET(B) receptors to the physiopathology of ischemic acute
Autor:
Jean-Marie Ketelslegers, André A. Charlier, PE Massart, Henri Van Mechelen, Olivier Laloux, Jean-Paul Clozel, Julian Donckier, Dominique Hodeige, Guy R. Heyndrickx
Publikováno v:
Circulation. 96:1250-1256
Background Endothelin-1 (ET-1) may play a role in hypertension. ET-1 receptor antagonism by bosentan lowers blood pressure in hypertension. We evaluated whether the effect of bosentan is still observed under ACE inhibitors (ACEI). Methods and Results
Autor:
Walter Fischli, Arlene Wolny, Josiane Rein, Paul Vogt, Jean-Paul Clozel, Marko Turino, Wolfgang Kiowski, Paul Mory
Publikováno v:
Circulation Research. 80:219-227
Blockade of the renin-angiotensin system by inhibition of angiotensin-converting enzyme (ACE) is beneficial for the treatment of hypertension and congestive heart failure. However, it is unclear how complete the blockade by ACE inhibitors is and if t
Publikováno v:
Cardiovascular Drugs and Therapy. 11:723-739
Low-voltage–activated T-type Ca2+ channelsare present in most excitable tissues including the heart (mainly pacemakercells), smooth muscle, central and peripheral nervous systems, and endocrinetissues, but also in non-excitable cells, such as osteo
Publikováno v:
Journal of Hypertension. 15:S17-S26
PROPERTIES OF MIBEFRADIL: Mibefradil is a novel calcium channel antagonist with structural and pharmacological characteristics clearly distinct from those of classical calcium antagonists. It is a potent vasodilator with a high selectivity for the co
Publikováno v:
Journal of Hypertension. 15:S11-S18
Calcium antagonistsCalcium antagonists are potent vasodilators and are widely used in the treatment of hypertension and angina pectoris. The currently available compounds belong to three classes: (1) dihydropyridines (e.g. nifedipine, amlodipine, fel
Autor:
Jean-Paul Clozel
Publikováno v:
Cardiology. 88:4-8